Display options
Cite
Wang J, Yu X, Barnes G, et al. The effects of tislelizumab plus chemotherapy as first-line treatment on health-related quality of life of patients with advanced squamous non-small cell lung cancer: Results from a phase 3 randomized clinical trial. Cancer Treat Res Commun. 2021;30:100501doi: 10.1016/j.ctarc.2021.100501.
Wang, J., Yu, X., Barnes, G., Leaw, S., Bao, Y., & Tang, B. (2021). The effects of tislelizumab plus chemotherapy as first-line treatment on health-related quality of life of patients with advanced squamous non-small cell lung cancer: Results from a phase 3 randomized clinical trial. Cancer treatment and research communications, 30100501. https://doi.org/10.1016/j.ctarc.2021.100501
Wang, J, et al. "The effects of tislelizumab plus chemotherapy as first-line treatment on health-related quality of life of patients with advanced squamous non-small cell lung cancer: Results from a phase 3 randomized clinical trial." Cancer treatment and research communications vol. 30 (2021): 100501. doi: https://doi.org/10.1016/j.ctarc.2021.100501
Wang J, Yu X, Barnes G, Leaw S, Bao Y, Tang B. The effects of tislelizumab plus chemotherapy as first-line treatment on health-related quality of life of patients with advanced squamous non-small cell lung cancer: Results from a phase 3 randomized clinical trial. Cancer Treat Res Commun. 2021 Dec 17;30:100501. doi: 10.1016/j.ctarc.2021.100501. Epub 2021 Dec 17. PMID: 34952253.
Copy Download .nbib Format: NLM
Share it on

Cancer Treat Res Commun. 2021 Dec 17;30:100501. doi: 10.1016/j.ctarc.2021.100501. Epub 2021 Dec 17.

The effects of tislelizumab plus chemotherapy as first-line treatment on health-related quality of life of patients with advanced squamous non-small cell lung cancer: Results from a phase 3 randomized clinical trial.

Cancer treatment and research communications

J Wang, X Yu, G Barnes, S Leaw, Y Bao, B Tang

Affiliations

  1. Department of Parenteral and Enteral Nutrition, State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address: [email protected].
  2. Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
  3. Health Economics and Outcomes Research, BeiGene, Ltd., Emeryville, CA, USA.
  4. Clinical Development, BeiGene (Shanghai) Co., Ltd., Shanghai, China.

PMID: 34952253 DOI: 10.1016/j.ctarc.2021.100501

Abstract

BACKGROUND: This study assessed the effects of adding tislelizumab to first-line standard-of- care chemotherapy on the health-related quality of life (HRQoL) of patients with advanced squamous non-small cell lung cancer (sq-NSCLC).

PATIENTS AND METHODS: Patients in this open-label, multicenter, phase 3 RATIONALE 307 trial were randomized to one of the three arms: tislelizumab plus carboplatin and paclitaxel (Arm A), tislelizumab plus carboplatin and nab-paclitaxel (Arm B), or paclitaxel plus carboplatin (Arm C). HRQoL was measured using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) and the EORTC Quality of Life Questionnaire Lung Cancer 13-item module (QLQ-LC13). Mean score change from baseline at Weeks 6 and 12 in the QLQ-C30's global health status/quality of life (GHS/QoL), fatigue, and physical functioning scores and QLQ-LC13 lung cancer specific subscales were examined. Time to deterioration was estimated for the GHS/QoL score.

RESULTS: A total of 355 sq-NSCLC patients received at least one dose of study drug and completed at least one HRQoL assessment. The GHS/QoL scores improved in Arms A and B relative to Arm C at Weeks 6 and 12. Arms A and B also experienced a reduction in most lung cancer-specific symptoms relative to Arm C. Time to deterioration of GHS/QoL was not reached by any of the three arms.

CONCLUSIONS: The addition of tislelizumab to platinum-based chemotherapy is associated with improvements in sq-NSCLC patients' HRQoL, especially in GHS/QoL and most importantly in lung cancer-specific symptoms including coughing, dyspnea, and hemoptysis.

Copyright © 2021. Published by Elsevier Ltd.

Keywords: Health-related quality of life; Patient-reported outcomes; Phase 3; Programmed cell death protein-1 inhibitor; Squamous non-small cell lung cancer

Publication Types